اولاپاریب (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "اولاپاریب" in Persian language version.

refsWebsite

Global rank Persian rank

10nih.gov

4^th place

5^th place

5doi.org

2^nd place

4web.archive.org

1^st place

4europa.eu

68^th place

179^th place

4fda.gov

447^th place

382^nd place

2medicines.org.uk

3,823^rd place

1,188^th place

2cancerresearchuk.org

8,489^th place

2,164^th place

1mesowatch.com

low place

1icr.ac.uk

low place

1medium.com

551^st place

737^th place

1cancer.gov

1,684^th place

533^rd place

cancer.gov

"National Cancer Institute - Olaparib after Initial Treatment Delays Ovarian Cancer Progression".

cancerresearchuk.org

scienceblog.cancerresearchuk.org

"Coming ever closer – first PARP inhibitor licensed in Europe" (science blog). Cancer Research UK. 24 October 2014. Archived from the original on 30 March 2019. Retrieved 9 June 2021.

cancerresearchuk.org

"PARP inhibitors: Halting cancer by halting DNA repair". Cancer Research UK. 24 September 2020.

doi.org

Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. (July 2009). "Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers". The New England Journal of Medicine. 361 (2): 123–34. doi:10.1056/NEJMoa0900212. PMID 19553641.
Wiggans AJ, Cass GK, Bryant A, Lawrie TA, Morrison J (May 2015). "Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer". The Cochrane Database of Systematic Reviews (5): CD007929. doi:10.1002/14651858.CD007929.pub3. PMC 6457589. PMID 25991068.
Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. (August 2017). "Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation". The New England Journal of Medicine. 377 (6): 523–533. doi:10.1056/NEJMoa1706450. PMID 28578601.
Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, et al. (October 2019). "Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer". Cancer Discovery. 9 (10): 1372–1387. doi:10.1158/2159-8290.CD-19-0582. PMC 7319046. PMID 31416802.
Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, et al. (October 2008). "4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1". Journal of Medicinal Chemistry. 51 (20): 6581–6591. doi:10.1021/jm8001263. PMID 18800822.

europa.eu

ema.europa.eu

"Lynparza EPAR". European Medicines Agency (EMA). Retrieved 6 October 2020.
"Summary" (PDF). European Medicines Agency (EMA). Archived from the original (PDF) on 16 March 2018. Retrieved 9 June 2021.
"Lynparza EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 13 April 2020.

emea.europa.eu

"Olaparib for the treatment of ovarian cancer" (PDF). europa.eu.

fda.gov

"FDA approves Lynparza to treat advanced ovarian cancer". U.S. Food and Drug Administration (FDA) (Press release). 19 December 2014. Archived from the original on 19 December 2014. Retrieved 30 December 2019. This article incorporates text from this source, which is in the public domain.
"FDA approves olaparib for germline BRCA-mutated metastatic breast cancer". U.S. Food and Drug Administration (FDA). 12 January 2018. Retrieved 13 April 2020.
"FDA approves olaparib for adjuvant treatment of high-risk early breast". U.S. Food and Drug Administration (FDA). 11 March 2022. Retrieved 14 March 2022. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Drug Approval Package: Lynparza (olaparib) Capsules NDA #206162". U.S. Food and Drug Administration (FDA). 22 January 2015. Retrieved 13 April 2020.

icr.ac.uk

"KuDOS Pharmaceuticals: First Patient Treated with New Anti-cancer Agent" (press release). Institute of Cancer Research. 25 July 2005.

medicines.org.uk

"Lynparza 50 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 7 October 2019. Archived from the original on 23 September 2020. Retrieved 13 April 2020.
"Lynparza 100mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 7 October 2019. Retrieved 13 April 2020.

medium.com

"Olaparib: realising the promise of synthetic lethality". Cancer Research UK. 16 July 2015.

mesowatch.com

Article, MesoWatch. "Ovarian Cancer Patients Can Now Access Tumor Blocking Drug Olaparib at Beginning of the Treatment". "MesoWatch". Retrieved 9 June 2021.

nih.gov

pubmed.ncbi.nlm.nih.gov

Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. (July 2009). "Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers". The New England Journal of Medicine. 361 (2): 123–34. doi:10.1056/NEJMoa0900212. PMID 19553641.
Wiggans AJ, Cass GK, Bryant A, Lawrie TA, Morrison J (May 2015). "Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer". The Cochrane Database of Systematic Reviews (5): CD007929. doi:10.1002/14651858.CD007929.pub3. PMC 6457589. PMID 25991068.
Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. (August 2017). "Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation". The New England Journal of Medicine. 377 (6): 523–533. doi:10.1056/NEJMoa1706450. PMID 28578601.
Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, et al. (October 2019). "Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer". Cancer Discovery. 9 (10): 1372–1387. doi:10.1158/2159-8290.CD-19-0582. PMC 7319046. PMID 31416802.
Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, et al. (October 2008). "4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1". Journal of Medicinal Chemistry. 51 (20): 6581–6591. doi:10.1021/jm8001263. PMID 18800822.

dailymed.nlm.nih.gov

"Lynparza- olaparib capsule". DailyMed. 27 September 2018. Retrieved 30 December 2019.
"Lynparza- olaparib tablet, film coated". DailyMed. 1 June 2019. Retrieved 30 December 2019.
"Lynparza- olaparib tablet, film coated". DailyMed. 1 June 2019. Retrieved 30 December 2019.

ncbi.nlm.nih.gov

Wiggans AJ, Cass GK, Bryant A, Lawrie TA, Morrison J (May 2015). "Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer". The Cochrane Database of Systematic Reviews (5): CD007929. doi:10.1002/14651858.CD007929.pub3. PMC 6457589. PMID 25991068.
Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, et al. (October 2019). "Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer". Cancer Discovery. 9 (10): 1372–1387. doi:10.1158/2159-8290.CD-19-0582. PMC 7319046. PMID 31416802.

web.archive.org

"Lynparza 50 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 7 October 2019. Archived from the original on 23 September 2020. Retrieved 13 April 2020.
"Summary" (PDF). European Medicines Agency (EMA). Archived from the original (PDF) on 16 March 2018. Retrieved 9 June 2021.
"FDA approves Lynparza to treat advanced ovarian cancer". U.S. Food and Drug Administration (FDA) (Press release). 19 December 2014. Archived from the original on 19 December 2014. Retrieved 30 December 2019. This article incorporates text from this source, which is in the public domain.
"Coming ever closer – first PARP inhibitor licensed in Europe" (science blog). Cancer Research UK. 24 October 2014. Archived from the original on 30 March 2019. Retrieved 9 June 2021.